Below are the most recent publications written about "Receptors, Progesterone" by people in Profiles.
-
Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Unger JM, Tripathy D, Hortobagyi GN, Pusztai L, Kalinsky K. Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial. J Natl Cancer Inst. 2025 May 01; 117(5):889-897.
-
Kamaraju S, Fowler AM, Tarima S, Chaudhary LN, Burkard ME, Giever T, Cheng YC, Parkes A, Lange CA, Pipp-Dahm M, Hegeman R, Siddiqui N, Stella A, Rajguru S, Twaroski K, Zurbriggen L, Jorns JM, Rui H, Keigley QJ, Perlman SB, Salem K, Bradshaw TJ, Sahmoud T, Wisinski K. A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer. Clin Breast Cancer. 2025 Apr; 25(3):251-260.
-
Moh M, Puzyrenko A, Summey R, Rader JS, Herrera Cano GE, Gavina JV, Rui H, Sun Y, Hopp E. Clinicopathologic Characteristics of a Single-institution Cohort of Ovarian Adult Granulosa Cell Tumors, With Biomarker and Therapeutic Implications Utilizing the Detection of Androgen, Estrogen, and Progesterone Hormone Receptor Expression by Immunohistochemistry. Int J Gynecol Pathol. 2024 Sep 01; 43(5):527-534.
-
Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, Cristofanilli M, Meisel J, Miller KD, Abdou Y, Riley EC, Qamar R, Sharma P, Reid S, Sinclair N, Faggen M, Block CC, Ko N, Partridge AH, Chen WY, DeMeo M, Attaya V, Okpoebo A, Alberti J, Liu Y, Gauthier E, Burstein HJ, Regan MM, Tolaney SM. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. J Clin Oncol. 2024 06 10; 42(17):2050-2060.
-
Lee YJ, Yoo TK, Kim J, Chung IY, Ko BS, Kim HJ, Lee JW, Son BH, Ahn SH, Lee SB. Survival outcomes of breast cancer patients with recurrence after surgery according to period and subtype. PLoS One. 2023; 18(7):e0284460.
-
Sgroi DC, Treuner K, Zhang Y, Piper T, Salunga R, Ahmed I, Doos L, Thornber S, Taylor KJ, Brachtel E, Pirrie S, Schnabel CA, Rea D, Bartlett JMS. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. Breast Cancer Res. 2022 12 16; 24(1):90.
-
Cobain EF, Hayes DF. Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. J Clin Oncol. 2022 11 10; 40(32):3673-3676.
-
Matar R, Barrio AV, Sevilimedu V, Le T, Heerdt A, Morrow M, Tadros A. Can We Successfully De-Escalate Axillary Surgery in Women Aged = 70 Years with Ductal Carcinoma in Situ or Early-Stage Breast Cancer Undergoing Mastectomy? Ann Surg Oncol. 2022 Apr; 29(4):2263-2272.
-
Lee YJ, Hwang YS, Kim J, Ahn SH, Son BH, Kim HJ, Ko BS, Kim J, Chung IY, Lee JW, Lee SB. A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer. Sci Rep. 2021 12 06; 11(1):23509.
-
Guzm?n-Arocho YD, Rosenberg SM, Garber JE, Vardeh H, Poorvu PD, Ruddy KJ, Kirkner G, Snow C, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Brachtel EF, Marotti JD, Warner E, Partridge AH, Collins LC. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer. 2022 02; 126(2):302-309.